Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

Cumberland Pharmaceuticals Earnings Call: Key Takeaways

Cumberland transformed into an innovation-focused biopharma after selling its commercial portfolio for $100 million, shifting focus to its late-stage clinical pipeline led by Ifetroban.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthLegacy revenue discontinued; $11 million expected from inventory/transition services next year.
Mgmt ConfidenceHigh confidence in clinical team's 100+ years experience and regulatory strategy.
Margin TrendsEliminated $32 million in annual commercial expenses; interest income reached $0.8 million.
Op. LeverageTransitioned to lean R&D model; interest income covers current operating expenses.
Segment GrowthDMD program shows 5.4 percentage point improvement in ejection fraction (p=0.002).
New ClientsStrategic partnership with Apotex Health closed July 1st for $100 million.
Capex & DebtDebt-free after $5.2 million credit line repayment; $22 million special dividend paid.
RegulatoryPre-NDA meeting held; FDA granted rolling review for Ifetroban in DMD.
CommentaryStrategic pivot from commercial operations to high-value rare disease drug development.
New LaunchesPlanned NDA submission for Ifetroban (DMD); Phase 2 oncology follow-up study planned.

Growth

Net income reached $77.8 million including transaction gains; cash grew to $80.6 million.

Outlook

Cash reserves projected to fund operations for over five years.

Risks

Zero analyst questions were asked; management's reliance on natural history data for NDA approval.

Source

The company's earnings call, NASDAQ: CPIX, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Cumberland Pharmaceuticals Inc: key numbers

Share price
$5.80Close, Nov 17
Market cap
$87M
Shares outstanding
15MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Cumberland Pharmaceuticals Inc

All →
4:28 PM ET 8-K/A
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban in patients with systemic sclerosis (SSc). The study met its primary objective of demonstrating that ifetroban was generally well tolerated with a safety profile consistent with prior experience, though the trial was not powered to detect significant efficacy differences due to limited disease progression in both groups.

Term
12 months
4:28 PM ET 8-K/A
Business Update

Cumberland Pharmaceuticals Business Update

Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The FDA has granted a rolling submission for the application, which will use data from the FIGHT DMD trial compared against natural history databases. The decision to file follows several regulatory meetings where the company addressed FDA questions regarding Phase 2 study results and efficacy endpoints.

5:15 PM ET 10-Q
Financial Results

Cumberland Pharmaceuticals Q3 2026 Results: Turns Profitable, Net Income $77.8M

Cumberland Pharmaceuticals reported a significant net income of $77.8 million for the quarter ended September 30, 2026, primarily driven by an $81.1 million gain from the disposal of discontinued operations. Total revenue from continuing operations increased to $2.2 million, while the company declared a substantial cash dividend of $22.5 million during the period.

Key figure
Net income $77.8M
5:07 PM ET 8-K
Financial Results

Cumberland Pharmaceuticals Financial Results

Cumberland Pharmaceuticals reported Q3 2026 financial results, its first full quarter as a development-focused company following the $100 million divestiture of its commercial brands to Apotex Health. The company announced plans to submit a New Drug Application (NDA) to the FDA for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD) following a successful Phase 2 trial.

Term
Q3 2026

“Our first full quarter as a development-focused company has reinforced the value of concentrating our efforts on our clinical pipeline. Our team and resources are now dedicated to developing new medicines for unmet medical needs. We have the financial strength and the expertise to pursue our new mission, as we work to create lasting value for patients and shareholders.”

A.J. Kazimi, CEO of Cumberland Pharmaceuticals
4:41 PM ET 8-K
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced plans to submit a New Drug Application (NDA) for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The submission is supported by Phase 2 FIGHT DMD trial data showing a statistically significant 5.4% improvement in left ventricular ejection fraction (LVEF) compared to a control group. While the FDA expressed concerns regarding the sufficiency of the data package for efficacy requirements, the company is moving forward with the submission following a pre-NDA meeting.

Counterparty
FDA
5:02 PM ET 8-K
Clinical Trial Data

Cumberland Pharmaceuticals Clinical Trial Data

Cumberland Pharmaceuticals announced top-line results from its Phase 2a ASSIST-SSc clinical trial evaluating oral ifetroban in patients with systemic sclerosis. The study results supported the safety and tolerability of the drug candidate in this rare disease population.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.